Multiple myeloma – DREAMM-7 update
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, one of the authors of the DREAMM7 study, gave a summary
From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
In-depth stories
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, one of the authors of the DREAMM7 study, gave a summary
Prof Claudio Cerchione, a haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori in Meldola, Italy, presented pioneering research at the ASCO24 rapid oral abstract
Project in the spotlight
Dr Lucia Perez-Lamas, a haematologist at the Puerta de Hierro University Hospital in Madrid, Spain, presented real-world evidence on the use of momelotinib in myelofibrosis (MF) patients with anaemia.
Dr Adriano Salaroli, a haematologist at the Institut Jules Bordet in Brussels, provides an update on cytopenic myelofibrosis, emphasising the need for increased awareness regarding this specific subtype of myelofibrosis.
Dr Marie Vercruyssen, a haematologist at the Institut Jules Bordet in Brussels, summarised the outcomes of the IMROZ trial, which evaluated the addition of the anti-CD38 monoclonal antibody isatuximab to
Dr Sigrún Thorsteinsdóttir, a haematologist at Rigshospitalet in Copenhagen, Denmark, also holds a position as a postdoctoral researcher in the iStopMM study at the University of Iceland. The iSTOPMM study
Dr Hanne Norseth, a haematologist at the Oslo Myeloma Center in Norway, presented the results of the phase I/II TG01 study. This study evaluates the safety and efficacy of the
At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, highlights the necessity for novel treatment combinations in lenalidomide-refractory MM patients. Belantamab
During EHA 2024, an entire session was dedicated to the management of difficult to treat multiple myeloma (MM) populations. In this session, Dr Claudia Stege, haematologist at the Erasmus Medical
In-depth stories
Dr Lucia Perez-Lamas, a haematologist at the Puerta de Hierro University Hospital in Madrid, Spain, presented real-world evidence on the use of momelotinib in myelofibrosis (MF) patients with anaemia.
Dr Adriano Salaroli, a haematologist at the Institut Jules Bordet in Brussels, provides an update on cytopenic myelofibrosis, emphasising the need for increased awareness regarding this specific subtype of myelofibrosis.
Dr Marie Vercruyssen, a haematologist at the Institut Jules Bordet in Brussels, summarised the outcomes of the IMROZ trial, which evaluated the addition of the anti-CD38 monoclonal antibody isatuximab to
Dr Sigrún Thorsteinsdóttir, a haematologist at Rigshospitalet in Copenhagen, Denmark, also holds a position as a postdoctoral researcher in the iStopMM study at the University of Iceland. The iSTOPMM study
Dr Hanne Norseth, a haematologist at the Oslo Myeloma Center in Norway, presented the results of the phase I/II TG01 study. This study evaluates the safety and efficacy of the
At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, highlights the necessity for novel treatment combinations in lenalidomide-refractory MM patients. Belantamab
During EHA 2024, an entire session was dedicated to the management of difficult to treat multiple myeloma (MM) populations. In this session, Dr Claudia Stege, haematologist at the Erasmus Medical
Poster selection
Dr. Gustav Cederquist from the Memorial Sloan Kettering Cancer Center, New Yorkevaluated the potential of brain radiotherapy as an effective bridge for chemo-refractory or progressive secondary CNS lymphoma.
Central nervous system (CNS) relapse in diffuse large B-cell lymphoma is associated with poor outcomes necessitating the identification of high-risk patients. To refine CNS risk stratification, a better understanding of
Enteropathy associated T-cell lymphoma is a rare peripheral T-cell lymphoma with a poor prognosis. Dr. Frederik Meeuwes, hematologist from the Treant hospital in Emmen presented a population-based cohort study on
Vera De Jonge, PhD student from the VUMC, Amsterdam and Joanna Bult, PhD student from the University Medical Center Groningen assessed the impact of a rearrangement of the MYC oncogene
What is the impact of BCR stimulation on miRNA content in CLL cells and EVs? And what is the impact of CLL-EVs on moncytes? That’s what this study aims to
This study identifies the role of PSOP1 in the initiation and maintenance of T-ALL, by analyzing the effects caused by PSIP1 loss, both in mice models and human T-ALL cell
The aim of this project is to determine the effective concentration (EC) of TXA using the GFC/LT, to facilitate TXA use in surgery or trauma. For this, the research team
The aim of this project is to determine the effective concentration (EC) of TXA using the GFC/LT, to facilitate TXA use in surgery or trauma. For this, the research team